Stereotactic radiosurgery using a self-shielded gyroscopic radiosurgery system for meningiomas: technical aspects and dosimetric results.
Independent dose calculations closely matched ZAP-X planning system calculations for meningioma radiosurgery.
Stereotactic radiosurgery using a self-shielded gyroscopic radiosurgery system for meningiomas: technical aspects and dosimetric results.
The ZAP-X ® Gyroscopic Radiosurgery ® platform (ZAP Surgical Systems, Inc., San Carlos, CA, USA) is a novel self-shielded image-guided radiotherapy device developed for frameless stereotactic radiosurgery (stereotactic radiosurgery) and fractionated stereotactic radiosurgery (fractionated SRS) of intracranial and cervical spine lesions.
This article presents technical aspects and dosimetric results for stereotactic radiosurgery and fractionated SRS using the ZAP-X system for meningioma patients.
Unique technical aspects of our treatment workflow using the ZAP-X system encompassing computed tomography simulation, treatment planning, independent dose calculations, patient-specific quality assurance (patient-specific quality assurance) and treatment delivery were described.
For Group A, mean age (range) was 60 years (35 years - 80 years) and mean planning target volume (planning target volume) (range) was 4.78 cc (2.10 cc - 9.38 cc).
Mean (range) planning target volume coverage, prescribed isodose line, Paddick conformity index, gradient index, number of isocenters, number of beams, delivery time estimate per fraction and patient-specific quality assurance gamma passing rate were 99.5% (99.5% - 99.6%), 53.5% (50.1% - 61.3%), 0.89 (0.83-0.93), 2.64 (2.54-2.88), 11.8 (5-19), 208.5 (91-332), 43.6 min (24.5 -61.0 min) and 95.0% (91.5% - 98.4%), respectively.
Our experience with stereotactic radiosurgery and fractionated SRS using the ZAP-X system for meningioma patients demonstrated that a typical external beam radiotherapy workflow was applicable with unique technical aspects, and treatment plans met our institutional planning goals and were concordant with independent dose calculations and patient-specific quality assurance.